Current Rating and Its Context
On 29 December 2025, MarketsMOJO revised the rating for Auro Laboratories Ltd from 'Hold' to 'Sell', reflecting a significant change in the company’s overall assessment. The Mojo Score, a composite indicator of the stock’s attractiveness, declined by 16 points, moving from 51 to 35. This score and rating encapsulate a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical factors as of the rating update date.
Here’s How the Stock Looks Today
As of 23 January 2026, Auro Laboratories Ltd remains classified as a microcap within the Pharmaceuticals & Biotechnology sector. The current Mojo Grade is 'Sell', consistent with the rating update from late December. Investors should note that all financial data, returns, and fundamental metrics referenced here are current as of today, providing a real-time perspective rather than historical snapshots from the rating change date.
Quality Assessment
The company’s quality grade is assessed as average. This reflects a middling operational and financial health profile. Auro Laboratories faces challenges in servicing its debt, with a Debt to EBITDA ratio of 3.58 times, indicating a relatively high leverage burden. Such a ratio suggests limited flexibility in managing debt obligations, which can constrain growth and increase financial risk.
Moreover, the company’s long-term growth trajectory has been disappointing. Over the past five years, net sales have declined at an annualised rate of -13.87%, while operating profit has contracted by -20.09% annually. These figures highlight persistent operational difficulties and a shrinking revenue base, which weigh heavily on the company’s quality rating.
Valuation Considerations
Currently, Auro Laboratories is considered very expensive relative to its earnings and capital employed. The stock trades at an Enterprise Value to Capital Employed ratio of 2.1, which is high given the company’s subdued returns. Its Return on Capital Employed (ROCE) stands at a low 2.5%, signalling poor efficiency in generating profits from its capital base.
Despite the high valuation multiples, the stock is trading at a discount compared to its peers’ average historical valuations. This suggests that while the company is expensive on an absolute basis, relative to sector benchmarks there may be some valuation cushion. However, this relative discount has not translated into positive returns for investors.
Financial Trend Analysis
The financial trend for Auro Laboratories is flat, indicating stagnation rather than growth or decline in recent periods. The company reported a flat performance in the nine months ending September 2025, with a Profit After Tax (PAT) of ₹1.00 crore, which represents a sharp decline of -70.85% compared to prior periods. This steep fall in profitability is a critical concern for investors assessing the company’s earnings sustainability.
Over the past year, the stock has delivered a negative return of -12.93%, reflecting investor caution amid deteriorating fundamentals. Profitability has fallen by approximately -83% over the same period, underscoring the challenges faced by the company in reversing its downward trend.
Technical Outlook
The technical grade for Auro Laboratories is mildly bearish. Recent price movements show volatility with short-term gains offset by longer-term declines. For instance, the stock’s one-day change is a slight decline of -0.07%, while the one-week return is a modest +3.06%. However, over one month and six months, the stock has declined by -14.74% and -18.78% respectively, indicating downward momentum.
These technical signals suggest that the stock is under selling pressure and lacks strong upward momentum, which aligns with the overall 'Sell' rating. Investors relying on technical analysis may view this as a cautionary sign to avoid initiating new positions at current levels.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
What This Rating Means for Investors
The 'Sell' rating on Auro Laboratories Ltd signals that the stock is currently viewed as unattractive for investment based on its present fundamentals and market position. The combination of average quality, very expensive valuation, flat financial trends, and mildly bearish technicals suggests limited upside potential and elevated risk.
Investors should interpret this rating as a caution to either avoid initiating new positions or consider reducing existing exposure. The company’s weak growth prospects, deteriorating profitability, and high leverage present significant headwinds that may continue to pressure the stock price.
However, the relative valuation discount compared to peers may offer some value for contrarian investors willing to accept higher risk. Close monitoring of upcoming quarterly results and any strategic initiatives by management will be essential to reassess the stock’s outlook in the future.
Summary of Key Metrics as of 23 January 2026
- Mojo Score: 35.0 (Sell Grade)
- Debt to EBITDA Ratio: 3.58 times
- Net Sales Growth (5 years): -13.87% CAGR
- Operating Profit Growth (5 years): -20.09% CAGR
- PAT (9M Sep 2025): ₹1.00 crore, down -70.85%
- ROCE: 2.5%
- Enterprise Value to Capital Employed: 2.1
- Stock Returns: 1D: -0.07%, 1W: +3.06%, 1M: -14.74%, 3M: +5.07%, 6M: -18.78%, YTD: -9.44%, 1Y: -12.93%
In conclusion, Auro Laboratories Ltd’s current 'Sell' rating reflects a comprehensive evaluation of its financial health, valuation, and market performance as of today. Investors should weigh these factors carefully when considering their portfolio strategies.
Unlock special upgrade rates for a limited period. Start Saving Now →
